- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.
Cellectis is taking another step to move immunotherapy 'off the shelf.'
The pharmaceutical company has signed a deal to sell its intrathecal therapy segment to a Piramal Enterprises subsidiary for up to $203 million.